Full Title
A Phase I Study of Alectinib plus Duvelisib in Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ ALCL)Purpose
Anaplastic large cell lymphoma (ALCL) is a type of T-cell cancer. This cancer has a fusion (change) in the ALK gene. The fusion gene makes a protein that promotes cancer growth and survival. This type of cancer is called ALK-positive ALCL.
One common treatment for people with ALK-positive ALCL that came back or keeps growing after treatment are drugs called ALK inhibitors, including alectinib. It works by blocking the ALK fusion protein. These drugs work well. But people usually have to take them for long periods of time, because there is a risk of the lymphoma returning.
Researchers are assessing the addition of the drug duvelisib to alectinib. Duvelisib is a pill that researchers think will make alectinib work better. They hope this treatment is a safe and effective combination that can be taken for a limited amount of time and allow people to stop treatment. They are seeking the highest doses of alectinib and duvelisib that can be used safely when they are given together. Both drugs are taken orally (by mouth).
Who Can Join
To join this study, there are a few conditions. You must:
- Have ALK-positive ALCL that came back or keeps growing after treatment.
- Have completed prior anti-cancer medications at least 1 week before taking the study therapy.
- Be able to walk and do routine activities for more than half the time you are awake.
Contact
For more information or to see if you can join this study, please call Dr. Robert Stuver’s office at 646-608-4308.